Screening for depressive symptoms in patients with unresectable lung cancer.

Screening for depressive symptoms in patients with unresectable lung cancer. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Screening for depressive symptoms in patients with unresectable lung cancer. Abstract Text:

S ,J A Correa,E Dajczman,G Kasymjanova,H Kreisman,D Small,S ,J A Correa,E Dajczman,G Kasymjanova,H Kreisman,D Small,

INTRODUCTION: Early identification of psychological distress and depression is important to optimise the quality of life in patients with advanced non-small cell lung cancer (NSCLC). The prevalence of depression may vary, depending on the time since diagnosis of cancer, results of the treatment and the prognosis. The purpose of this study was to compare the efficacy of a self-administered screening tool (Hospital Anxiety and Depression Scale (HADS)) with a health professional administered tool (Montgomery-Asberg Depression Rating Scale (MADRS)) and to explore the variability of major affective symptoms in patients with unresectable lung cancer during the initial 7-8 weeks of chemotherapy treatment for their illness. MATERIAL AND METHODS: Patients with newly diagnosed unresectable lung cancer were screened on four occasions for anxiety and depressive symptoms simultaneously using the self-rated HADS and the MADRS administered by a psycho-oncologist or a trained research associate. The first assessment was done within 1 week of diagnosis and was repeated on 3 occasions during the initial 2 cycles of chemotherapy. RESULTS: Forty-nine patients, aged 38-82 years (median age 63 years) were enrolled. All patients had advanced NSCLC (stages 3A, 3B and 4) and 61% (30 patients) had an ECOG performance status (PS) of 1 or greater. The point prevalence of depression measured by an interviewer using the MADRS at visits 1-4 was 49%, 51%, 47%, and 41%, respectively. The point prevalence of self-reported depression (HADS) was significantly (p < 0.001) lower at each assessment point (18%, 20%, 6%, 12%) compared to health professional detected depression (MADRS). Although MADRS and HADS showed very strong (Pearson's correlation = 0.8) and significant (p < 0.001) correlation, the concordance rate in identifying the same cases of depression was only 54%. CLINICAL IMPLICATION AND CONCLUSION: The prevalence of depression among advanced lung cancer patients is high and varies very little during the first 2 cycles of chemotherapy. Among a variety of tools available for the screening of depression, a semi-structured interview is more effective at identifying clinically significant depression than a self-administered questionnaire.

Screening for depressive symptoms in patients with unresectable lung cancer. Publishing Authors By Initials

S ,JA Correa,E Dajczman,G Kasymjanova,H Kreisman,D Small,S ,JA Correa,E Dajczman,G Kasymjanova,H Kreisman,D Small,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Screening for depressive symptoms in patients with unresectable lung cancer. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Supportive care in cancer : official journal of th

VOLUME: 15

Page Numbers: 1207-12

Journal Abbreviation:

ISSN: 0941-4355

DAY: 14

MONTH: 02

YEAR: 2007

Screening for depressive symptoms in patients with unresectable lung cancer. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9302957

Screening for depressive symptoms in patients with unresectable lung cancer. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Screening for depressive symptoms in patients with unresectable lung cancer. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Screening for depressive symptoms in patients with unresectable lung cancer.

AFFILIATION: Division of Psychology, Department of Psychiatry, Jewish General Hospital, 3755 Cote St Catherine Rd, Montreal, H3T 1E2, Canada.

Country: Germany

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Support Care Cancer

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Screening for depressive symptoms in patients with unresectable lung cancer Related Publications

• 281.
• Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
• Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study.
• An in vivo correlate of exercise-induced neurogenesis in the adult dentate gyrus.
• Blank augmentation protocol for improving the robustness of multivariate calibrations.
• CA3 NMDA receptors are required for experience-dependent shifts in hippocampal activity.
• Cognitive deficits in preclinical Alzheimer's disease and vascular dementia: patterns of findings from the Kungsholmen Project.
• Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells.
• Globally distributed mycobacterial fish pathogens produce a novel plasmid-encoded toxic macrolide, mycolactone F.
• Hearing lips and seeing voices: how cortical areas supporting speech production mediate audiovisual speech perception.
• Imaging the earliest stages of Alzheimer's disease.
• Imaging-guided microarray: isolating molecular profiles that dissociate Alzheimer's disease from normal aging.
• Jagged-1hi or Delta-1hi thymic stromal cell populations can trigger acquisition of Thy-1 and loss of B220.
• Longitudinal mapping of mouse cerebral blood volume with MRI.
• Molecular evolution of the Li/li chemical defence polymorphism in white clover (Trifolium repens L.).
• Photoacoustic characterization of protein dynamics following CO photodetachment from fully reduced bovine cytochrome c oxidase.
• Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.
• Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways.
• Psychosocial functioning of adults who experienced substance use disorders as adolescents.
• Quantitative determination of ethanol in heated plumes by passive Fourier transform infrared remote sensing measurements.
• Repetition suppression for spoken sentences and the effect of task demands.
• Screening for depressive symptoms in patients with unresectable lung cancer.
• Selective expression of an aP2/Fatty Acid Binding Protein 4-Cre transgene in non-adipogenic tissues during embryonic development.
• Spectral simulation methodology for calibration transfer of near-infrared spectra.
• Speech-associated gestures, Broca's area, and the human mirror system.
• Task-dependent changes in brain activation following therapy for nonfluent aphasia: discussion of two individual cases.
• The mind of expert motor performance is cool and focused.
• Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease.
• Trying to detect taste in a tasteless solution: modulation of early gustatory cortex by attention to taste.
• Using the COPE intervention for family caregivers to improve symptoms of hospice homecare patients: a clinical trial.